-
Product Insights
NewNet Present Value Model: Kazia Therapeutics Ltd’s Paxalisib
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Paxalisib in Metastatic Brain Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Paxalisib in Metastatic Brain Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Paxalisib in Metastatic Brain Tumor Drug Details: Paxalisib is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Paxalisib in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Paxalisib in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Paxalisib in Glioblastoma Multiforme (GBM) Drug Details: Paxalisib is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Paxalisib in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Paxalisib in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Paxalisib in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis)...
-
Product Insights
Atypical Teratoid Rhabdoid Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Atypical Teratoid Rhabdoid Tumor - Drugs In Development, 2023’, provides an overview of the Atypical Teratoid Rhabdoid Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Atypical Teratoid Rhabdoid Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Primary CNS Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary CNS Lymphoma - Drugs In Development, 2023’, provides an overview of the Primary CNS Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary CNS Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Anaplastic Astrocytoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Anaplastic Astrocytoma - Drugs In Development, 2023’, provides an overview of the Anaplastic Astrocytoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Gliosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Gliosarcoma - Drugs In Development, 2023’, provides an overview of the Gliosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gliosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) - Drugs In Development, 2023’, provides an overview of the Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...